ANNE TSAO to Immunotherapy
This is a "connection" page, showing publications ANNE TSAO has written about Immunotherapy.
Connection Strength
1.010
-
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J Clin Oncol. 2022 02 20; 40(6):681-692.
Score: 0.301
-
Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol. 2019 02 14; 20(2):18.
Score: 0.247
-
Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638.
Score: 0.202
-
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).
Score: 0.073
-
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.
Score: 0.058
-
Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer. 2009 Jan; 10(1):36-41.
Score: 0.031
-
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
Score: 0.023
-
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
Score: 0.021
-
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Dec; 174:112-117.
Score: 0.020
-
Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report. J Intensive Care Med. 2022 Aug; 37(8):1055-1059.
Score: 0.019
-
Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nat Cancer. 2020 02; 1(2):176-183.
Score: 0.016